Patients' expression of CEACAM5 might hold the key to activity after all.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.